ArticleiScience2026
Optimization of hinge domain enhances antitumor efficacy of globo H-targeted CAR-T cells in solid tumor models.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor (CAR)-T cell therapy has shown remarkable efficacy in hematologic malignancies but remains limited in solid tumors. Globo-H, a glycosphingolipid overexpressed in epithelial cancers with restricted normal expression, is an attractive target. Globo-H-targeted vaccines and antibody-drug conjugates have demonstrated safety and antitumor activity. Although Globo-H CAR-T cells have been tested with different costimulatory domains, the impact of hinge configuration on CAR-T function remains largely unexplored. Here, we compare CD8α, CD28, and IgG4 hinges within a 4-1BB-based CAR framework. CD8α-hinge CAR-T cells exhibited superior activation, cytokine release, and cytotoxicity against Globo-H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.